Get the Stockscreener App
3.62
1.63%
-0.06
Mdxhealth Sa stock is traded at $3.62, with a volume of 71,712.
It is down -1.63% in the last 24 hours and down -5.73% over the past month.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
See More
Previous Close:
$3.68
Open:
$3.64
24h Volume:
71,712
Relative Volume:
0.49
Market Cap:
$185.94M
Revenue:
$63.69M
Net Income/Loss:
$-44.82M
P/E Ratio:
-1.81
EPS:
-2
Net Cash Flow:
$-30.56M
1W Performance:
+5.85%
1M Performance:
-5.73%
6M Performance:
+24.83%
1Y Performance:
+93.58%
1-Day Range:
$3.60
$3.69
1-Week Range:
$3.40
$3.73
52-Week Range:
$1.35
$5.33
Mdxhealth Sa Stock (MDXH) Company Profile
Compare MDXH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDXH
Mdxhealth Sa
|
3.62 | 189.02M | 63.69M | -44.82M | -30.56M | -2.00 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Mdxhealth Sa Stock (MDXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Initiated | Craig Hallum | Buy |
| Oct-31-24 | Initiated | Lake Street | Buy |
| May-31-23 | Initiated | TD Cowen | Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mdxhealth Sa Stock (MDXH) Latest News
MDxHealth (MDXH) Projected to Post Quarterly Earnings on Thursday - Defense World
Bearish Setup: What are MDxHealth SAs earnings expectationsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Outlook: Should I invest in MDxHealth SA before earningsQuarterly Trade Report & Expert Curated Trade Ideas - baoquankhu1.vn
MDxHealth to Release Q4 and Full Year 2025 Financial Results on February 26, 2026, Followed by Conference Call - Quiver Quantitative
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - The Manila Times
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewswire Inc.
Bond Watch: Whats the RSI of MDxHealth SA stock2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
Can MDxHealth SA stock continue upward trendWeekly Loss Report & Stock Portfolio Risk Management - mfd.ru
MDxHealth Details Exosome Diagnostics Deal and Restructured GPS Earnout Obligations - TipRanks
Will MDxHealth SA stock benefit from infrastructure spendingGold Moves & Low Risk Growth Stock Ideas - mfd.ru
Trading Action: Should I invest in MDxHealth SA before earningsJuly 2025 Earnings & Daily Volume Surge Signals - baoquankhu1.vn
Aug Shorts: Can Xcel Energy Inc disrupt its industryTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Trend Recap: Whats the RSI of MDxHealth SA stockGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
MDxHealth SA (NASDAQ:MDXH) Short Interest Update - MarketBeat
MDxHealth SA (NASDAQ:MDXH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Midday Stock Roundup: MDxHealth Up 9% Since Preliminary Q4, FY Results - Orange County Business Journal
Analysts Expect Breakeven For MDxHealth SA (NASDAQ:MDXH) Before Long - Sahm
MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest - MarketBeat
Retail Surge: How interest rate cuts could boost MDxHealth SA stockSwing Trade & Community Trade Idea Sharing Platform - Bộ Nội Vụ
MDxHealth Posts Preliminary 2025 Results, Expects Revenue Growth Of 26% To 28% In 2026 - Nasdaq
MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance By Investing.com - Investing.com India
MDxHealth Sees Over 20% Revenue Growth in Q4, Full Year - Orange County Business Journal
MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance - Investing.com
MDXH Projects Strong Revenue Growth and Ambitious 2026 Targets - GuruFocus
MDxHealth sees Q4 revenue $30.5M, consensus $26.18M - TipRanks
MDxHealth Posts Strong 2025 Revenue Growth, Sets 2026 Outlook and Revises Exact Sciences Earnout - TipRanks
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences - The Manila Times
Redlands Daily Facts - FinancialContent
MDxHealth (NASDAQ:MDXH) and Biotricity (OTCMKTS:BTCY) Critical Survey - Defense World
How MDxHealth SA stock reacts to job market data2025 Geopolitical Influence & Technical Entry and Exit Tips - ulpravda.ru
Will MDxHealth SA stock attract ESG investors2025 Big Picture & Proven Capital Preservation Methods - ulpravda.ru
Analyst Downgrade: How MDxHealth SA stock reacts to inflationary pressures2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Is MDxHealth SA stock dividend yield sustainableWeekly Market Report & Consistent Income Trade Ideas - Улправда
How MDxHealth SA stock reacts to inflationary pressuresTrade Analysis Summary & AI Forecast for Swing Trade Picks - Улправда
Can MDxHealth SA stock resist sector downturnsJuly 2025 Fed Impact & Capital Protection Trade Alerts - Улправда
MDxHealth announces next phase of collab with University of Oxford - MSN
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term - Yahoo Finance
MDxHealth SAOrdinary Shares (NQ: MDXH - FinancialContent
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer - The Manila Times
World’s largest prostate cancer trial adds genomic test to guide care - Stock Titan
MDxHealth SA (NASDAQ:MDXH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MDxHealth SA (NASDAQ:MDXH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
MDxHealth Files to Sell Up to $200 Million in Shares - marketscreener.com
MDxHealth SA to offer securities up to $200 millionSEC filing - marketscreener.com
Setup Watch: Will MDxHealth SA stock continue dividend increasesWeekly Trend Recap & Expert Verified Movement Alerts - Bộ Nội Vụ
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
MDXH: BTIG Reiterates Buy Rating with $7 Price Target | MDXH Sto - GuruFocus
BTIG reiterates Buy rating on MDxHealth stock, maintains $7 price target By Investing.com - Investing.com South Africa
BTIG Research Reaffirms "Buy" Rating for MDxHealth (NASDAQ:MDXH) - MarketBeat
BTIG reiterates Buy rating on MDxHealth stock, maintains $7 price target - Investing.com Australia
Mdxhealth Sa Stock (MDXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):